The Global Immuno-oncology Therapeutics Market—Checkpoint Inhibitors
The Global Immuno-oncology Therapeutics Market—Checkpoint Inhibitors
The Next Generation of Cancer Therapies
04-Jul-2016
North America
Description
Immuno-oncology is based on the premise that tumors escape detection by the immune system, contributing to their growth and progression. Checkpoint inhibitor pathways act as the checks and balances that allow T-cells to recognize foreign substances or tumors. This global study looks at the immune-oncology therapeutics pipeline for checkpoint inhibitors in the drug classes CTLA-4, PD-1/PD-L1, LAG-3, and TIM-3, identifying companies and products in development, dollars spent at each phase (preclinical through launch), cost and reimbursement implications to payers, challenges to commercialization, and opportunities for pharmaceutical, biotech, or diagnostic companies as oncology treatment algorithms evolve. The study period is 2011 to 2020.
Table of Contents
Scope and Segmentation
Key Questions this Study will Answer
Key Takeaways
Market Snapshot
Market Snapshot (continued)
8 Big Market Themes for Checkpoint Inhibitors
A Vibrant Ecosystem
Paradigm Expansion to Solid Tumor Cancer Therapies
Regional Launch Highlights
Game-changing Companies
Significant Investor Funding
Key 2016 Predictions—Checkpoint Inhibitor Market
Key Methodology and Scope
Checkpoint Inhibitor Drug Classes
Timeline of Checkpoint Product Approvals
Competitive Landscape—Target Segments, Count of Marketed and Pipeline Products
Checkpoint Segmentation by Subtype
Competitive Landscape—Target Product Counts by Phase
Checkpoint Pipelines by Company, Target, and Phase
Checkpoint Pipelines by Company, Target, and Phase (continued)
Checkpoint Pipelines by Company, Target, and Phase (continued)
Checkpoint Pipelines by Company, Target, and Phase (continued)
Checkpoint Target Segmentation
Competitive Landscape—CTLA-4/CAIX/GITR Segment, Products in Development
Competitive Landscape—PD-1/PD-L1 (programmed death 1-receptor)
Competitive Landscape—LAG-3 (lymphocyte activating gene 3)
Competitive Landscape—TIM-3 (T-cell immunoglobin and mucin domain 3)
PD-1 Product Dashboard—Keytruda® (Pembrolizumab): Merck & Co. (Marketed)
PD-1 Product Dashboard—Opdivo® (Nivolumab): Bristol-Myers Squibb/Ono (Marketed)
CTLA-4 Product Dashboard—Yervoy® (ipilimumab): Bristol-Myers Squibb (Marketed)
PD-L1 Product Dashboard—Tecentriq® (Atezolizumab): Roche (Marketed)
Competitive Overview of Established Companies
Checkpoint Inhibitors—PD-1/PD-L1
PD-L1 Product Dashboard—Avelumab (MSB0010718C): Merck KGaA (Phase III)
PD-L1 Product Dashboard—Durvalumab (MEDI-4736): AstraZeneca / MedImmune (Phase III)
Checkpoint Inhibitors—CTLA-4
CTLA-4 Product Dashboard—Tremelimumab (MEDI-1123): AstraZeneca (Phase III)
Immuno-oncology Combination Therapies
Checkpoint Combination Clinical Trials by Indication
Immuno-oncology Checkpoint Phase III Trials to Watch
Immuno-oncology Checkpoint Phase III Trials To Watch (continued)
Disruptive Technologies and Advances in this Field
Market Opportunities
Potential Game-changing Therapies
Overall Environmental Impact Factors
Checkpoint Product Patent Expirations
Biomarker Challenges
Opportunities in this Market—Escalating Drug Costs
Checkpoint Inhibitor Payer Environment
J-Codes, Annual Costs, and US Payers
Reimbursement Pathway—On-label Reimbursement Path
Reimbursement Pathway—Off-Label, Medicare
Reimbursement Pathway—Off-Label, Commercial Payers
Reimbursement Pathway—Off-Label, Commercial Payers (continued)
A Snapshot of Global Drug Price Control Methods
Pitfalls to Avoid
Companies to Watch
Companies to Watch (continued)
Checkpoint Inhibitor Forecast Sales Total—2020 ($20.5B)Actual Sales by Product
Investors Pour in Significant Funds
Checkpoint Milestones
2015 Deal and Financing—CTLA-4 Receptor Gene Therapy
2015 Deal and Financing Summary—PD-1/PD-L1
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—PD-1/PD-L1 (continued)
2015 Deal and Financing Summary—LAG-3
2015 Deal and Financing Summary—LAG-3 (continued)
2015 Deal and Financing Summary—LAG-3 (continued)
2015 Deal and Financing Summary—TIM-3
Key Conclusions
Growth Opportunities in 4 Checkpoint Inhibitor Segments
New Market Opportunities—Checkpoint Inhibitors
The Last Word—3 Big Predictions
Legal Disclaimer
Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development
Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)
Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)
Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)
Pipeline Analysis—CTLA-4/CAIX/GITR Segment, Products in Development (continued)
Pipeline Analysis—LAG-3 Products in Development
Pipeline Analysis—LAG-3 Products in Development (continued)
Pipeline Analysis—LAG-3 Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—PD-1/PD-L1 Segment, Products in Development (continued)
Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development
Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development (continued)
Pipeline Analysis—TIM-3 (T-cell immunoglobin and mucin domain 3) Segment, Products in Development (continued)
The Frost & Sullivan Story
Value Proposition: Future of Your Company & Career
Global Perspective
Industry Convergence
360º Research Perspective
Implementation Excellence
Related Research
Popular Topics
No Index | No |
---|---|
Podcast | No |
Author | Barbara Gilmore |
Industries | Healthcare |
WIP Number | MBA0-01-00-00-00 |
Is Prebook | No |